GGrantIndex
← Leaderboards

Esther Seunghee Oh

Johns Hopkins University

$5,646,106
Attributed
$7,720,745
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,720,745 · 6

By mechanism

R01$5,922,165 · 3
K23$818,775 · 1
T32$611,573 · 1
R21$368,232 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposS DiseaseMild Cognitive ImpairmentDementiaSamplingMeasurementLongitudinal StudiesAmyloid Beta-ProteinDisease ProgressionPathologyNursing HomesResponseSeveritiesFunctional DeclineMethodologyBaseBrainCaringInsightOutpatientsBiological MarkersCerebrospinal FluidIncidencePre-Clinical

Grant awards (18)

Addressing Hearing Loss as a Common Unmet Contributor to Neuropsychiatric Symptoms$752,953
R01 · FY2025 · AG · contact PI
Translational Aging Research Training Program$611,573
T32 · FY2025 · AG
Addressing Hearing Loss as a Common Unmet Contributor to Neuropsychiatric Symptoms$791,348
R01 · FY2024 · AG · contact PI
Addressing Hearing Loss as a Common Unmet Contributor to Neuropsychiatric Symptoms$806,858
R01 · FY2023 · AG · contact PI
Addressing Hearing Loss as a Common Unmet Contributor to Neuropsychiatric Symptoms$818,314
R01 · FY2022 · AG · contact PI
Does vestibular loss predict falls in patients with Alzheimer's Disease?$323,597
R01 · FY2022 · AG · contact PI
Clinical and Biological Predictors of Delirium and Long-term Cognitive Outcomes in COVID19 Patients$197,204
R01 · FY2021 · AG · contact PI
Novel Blood Biomarker of Alzheimer's disease Using Oral Glucose Tolerance$645,291
R01 · FY2020 · AG · contact PI
Novel Blood Biomarker of Alzheimer's disease Using Oral Glucose Tolerance$618,689
R01 · FY2019 · AG · contact PI
Novel Blood Biomarker of Alzheimer's disease Using Oral Glucose Tolerance$557,671
R01 · FY2018 · AG · contact PI
Novel Blood Biomarker of Alzheimer's disease Using Oral Glucose Tolerance$410,240
R01 · FY2017 · AG · contact PI
CSF predictors of postoperative delirium in non-demented hip fracture patients$163,755
K23 · FY2016 · AG · contact PI
CSF predictors of postoperative delirium in non-demented hip fracture patients$163,755
K23 · FY2015 · AG · contact PI
CSF predictors of postoperative delirium in non-demented hip fracture patients$163,755
K23 · FY2014 · AG · contact PI
CSF predictors of postoperative delirium in non-demented hip fracture patients$163,755
K23 · FY2013 · AG · contact PI
CSF predictors of postoperative delirium in non-demented hip fracture patients$163,755
K23 · FY2012 · AG · contact PI
Oral Glucose Tolerance Test for Alzheimer's Disease Biomarker Development$191,060
R21 · FY2011 · AG · contact PI
Oral Glucose Tolerance Test for Alzheimer's Disease Biomarker Development$177,172
R21 · FY2010 · AG · contact PI